1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. IMCD N.V.
  6. News
  7. Summary
    IMCD   NL0010801007

IMCD N.V.

(IMCD)
  Report
Real-time Euronext Amsterdam  -  05/18 11:36:03 am EDT
135.25 EUR   -1.42%
05/02IMCD N : PR AGM MB appointments
PU
05/02IMCD N : PR AGM adopt all resolutions 2022
PU
05/02IMCD N : announces Management Board re-appointments
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

IMCD presents Tomorrow's Pharmaceutical Industry: Insights into the global changes impacting the pharmaceutical sector, and the key trends that are shaping it

12/09/2021 | 04:12am EDT

Over the past year, IMCD has shared insights on some of the most prevalent topics and challenges within the food & nutrition, beauty & personal care, home care and I&I, coatings & construction, advanced materials, and lubricants & energy sectors. In this latest edition, IMCD's pharmaceuticals experts consider how shifting social, cultural, and healthcare priorities are influencing what patients are looking for and discuss four key trends that they have identified to be shaping the field of pharmaceuticals.


Patient-friendly dosage forms

It's critical to think about what makes a delivery system suitable for a patient to ensure compliance and therapeutic benefit. In an increasingly health-conscious world, it's important to adapt to meet the needs of every demographic. In this report, IMCD's experts discuss the new ways in which patient needs can be met, with dosage forms and beyond.


Pre-emptive healthy living

With the pandemic changing our perspectives on medicine, immunisation, and wellbeing, it's no surprise that a greater emphasis is being placed on proactive personal health. Whilst there is a clear distinction between pharma and nutra within the industry, it is also important to consider the synergies between the two categories. IMCD's nutraceutical experts explore the changing attitudes toward health, formulating challenges, and some of the substantial work being done in nutraceutical supplements to suit the demands of consumers.

Sustainable solutions

The topic of sustainability is one of the most relevant across every industry around the world. For API manufacturing, the environmental burden presents a challenge, as its entire business revolves around the production of medicines that help save lives. One of the key obstacles to overcome is recycling solvents, which is seldom a simple task. This is where IMCDhas the in-depth scientific expertise and understanding to help facilitate incremental change. One of our technical experts discusses this topic, as well as the biggest challenges when adopting a sustainable approach.

Pharma for the future

The COVID-19 pandemic has had a direct influence on biopharmaceutical science, or "Biopharma", in the last year. For example, the industry has invested in the research and refinement of vaccinations and monoclonal antibodies as solutions. More importantly, there has been a major area of innovation through biotechnology to help develop bespoke methods of treatment. In this section, IMCD provides an insight on the future of biopharma and the most exciting developments in the space.

IMCD Pharmaceuticals' mission is tocreate opportunities that advance ideas for a healthy future. We recognise the importance of collaborating with our partners to identify and analyse trends, to evolve and progress the pharmaceutical industry. We support our customers at every step of the product development process, driving Tomorrow's Pharmaceutical Industry by offering meaningful 360 solutions.

Click here to download your copy of the Tomorrow's Pharmaceutical Industry trends commentary, and to find out more about IMCD Pharmaceuticals.

For further questions, please reach out to our Media Relations team

Disclaimer

IMCD NV published this content on 09 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2021 09:11:09 UTC.


ę Publicnow 2021
All news about IMCD N.V.
05/02IMCD N : PR AGM MB appointments
PU
05/02IMCD N : PR AGM adopt all resolutions 2022
PU
05/02IMCD N : announces Management Board re-appointments
PU
05/02IMCD N.V. shareholders adopt all resolutions at AGM
GL
05/02IMCD N.V. shareholders adopt all resolutions at AGM
AQ
05/02IMCD announces Management Board (re)appointments
GL
05/02IMCD announces Management Board (re)appointments
AQ
05/02IMCD N.V. Appoints Marcus Jordan as Chief Operating Office and New Member of the Manage..
CI
05/02IMCD N : NV shareholders adopt all resolutions at AGM 2022
PU
05/02IMCD N : AGM 2022 Voting Results
PU
More news
Analyst Recommendations on IMCD N.V.
More recommendations
Financials
Sales 2022 4 085 M 4 287 M 4 287 M
Net income 2022 255 M 268 M 268 M
Net Debt 2022 875 M 918 M 918 M
P/E ratio 2022 29,8x
Yield 2022 1,28%
Capitalization 7 702 M 8 082 M 8 082 M
EV / Sales 2022 2,10x
EV / Sales 2023 1,97x
Nbr of Employees -
Free-Float 98,2%
Chart IMCD N.V.
Duration : Period :
IMCD N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMCD N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 135,25 €
Average target price 160,42 €
Spread / Average Target 18,6%
EPS Revisions
Managers and Directors
Pieter C. J. van der Slikke Chief Executive Officer
Hans Kooijmans Chief Financial Officer
Janus Smalbraak Chairman-Supervisory Board
Marcus Jordan Chief Operating Officer
Arjan J. T. Kaaks Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
IMCD N.V.-30.53%8 229
ECOLAB INC.-30.54%46 545
SIKA AG-30.56%40 876
GIVAUDAN SA-24.42%33 644
HENKEL AG & CO. KGAA-10.63%28 652
EMS-CHEMIE HOLDING AG-18.95%19 497